Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all
Open Access
- 16 November 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 15 (1), 13-20
- https://doi.org/10.1038/sj.cdd.4402255
Abstract
No abstract availableThis publication has 70 references indexed in Scilit:
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axisThe Journal of Experimental Medicine, 2007
- Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- The NEMO adaptor bridges the nuclear factor-κB and interferon regulatory factor signaling pathwaysNature Immunology, 2007
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Recognition of Cytosolic DNA Activates an IRF3-Dependent Innate Immune ResponseImmunity, 2006
- A Toll-like receptor–independent antiviral response induced by double-stranded B-form DNANature Immunology, 2005
- ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunityNature Immunology, 2005
- Molecular identification of a danger signal that alerts the immune system to dying cellsNature, 2003